MSME (Udyam registered) Ministry of MSME
- Category
- Small (2024-25)
- Udyam number
- UDYAM-GJ-06-0002450
Market Cap
₹22.22 Cr
HAMPS · BSE
Share Price
₹25.50
0.00% today
Revenue
₹8.47 Cr
FY 2025-26 · +27.0% YoY
EBITDA
₹0.04 Cr
Margin 0.5%
Net Profit
−₹0.73 Cr
FY 2025-26 · -343.3% YoY
Debt / Equity
0.58
Interest cover -32.0x
Authorised capital
₹10 Cr
Registered with MCA
Paid-up capital
₹8.71 Cr
Issued & subscribed
About Hamps Bio Limited
Data last updated:
Hamps Bio Limited is a public limited company based in Ankleshwar, Gujarat, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 02 January 2007 and has been in existence for over 19 years.
The company is registered with the Registrar of Companies (ROC), Ahmedabad, under CIN L24233GJ2007PLC049692. Its GSTIN is 24AABCH8058B1ZW (Gujarat). It is a listed company as per MCA records. Its shares are listed on BSE: 544312.
The company has an authorised share capital of ₹10 Cr and a paid-up capital of ₹8.71 Cr. It is led by directors including Herrik Mountbaton Shah (Managing Director) and Shrenikkumar Mountkumar Shah (Whole-Time Director).
Its last annual general meeting (AGM) was held on 30 August 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Surat, Gujarat.
As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹8.47 Cr, a growth of 27% compared to the previous year. For the same year it recorded a net loss of ₹73 Lakh (net margin -8.6%) and EBITDA of ₹4 Lakh (EBITDA margin 0.5%). The net worth stands at ₹8.1 Cr (down 8% YoY). Total assets are valued at ₹15.09 Cr (up 27.2% YoY).
The company has about 34 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Hampsbio. As per MCA filings, the company has open charges of ₹4.83 Cr on record. The company has 11 deals on record (10 market trades, 1 ipo); the latest was in July 2025. Its 6 peer companies in the Food and Beverages industry (Instant Foods, Pharma Retail and Distribution), with the same principal business activity (wholesale trading) are compared by revenue, 5 larger and 1 smaller; the largest is Aktis Pharma India Private Limited with revenue of ₹6.85 Cr.
Hamps Bio Limited is registered as a small enterprise under the Udyam registration framework (Reg. No. UDYAM-GJ-06-0002450). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website hampsbio.in.
Company details
CIN L24233GJ2007PLC049692
Registration Number 049692
Incorporation Date 02 January 2007
ROC Ahmedabad
Listing Status Listed - Listed on BSE (544312)
Company Status Active
Date of Last AGM 30 August 2025
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant
MSME Classification Small
Udyam Registration UDYAM-GJ-06-0002450
CIN history
Hamps Bio has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L24233GJ2007PLC049692, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24233GJ2007PLC049692 | Current |
| U24233GJ2007PLC049692 | Previous |
| U24233GJ2007PTC049692 | Previous |
Key People
Herrik Mountbaton Shah Managing Director Shrenikkumar Mountkumar Shah Whole-Time Director Shivali Rajpurohit Director Recognitions & Rankings of Hamps Bio
Contact details
Hamps Bio Limited's registered office is in Choryasi, Gujarat.
- Registered AddressPlot No C1 – B – 106 Nr – Mama Bhanja Factory, Bhatpore GIDC, Surat, Gujarat, India – 394510
- IndustryPharma, Drug Formulation & Development
Comprehensive company report
Hamps Bio Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
Hamps Bio operates one associated brand: Hampsbio. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Pharmaceutical formulations and freeze-dried food ingredients are manufactured. | hampsbio.com |
Financials of Hamps Bio Limited
FY 2025-26 filings availableHamps Bio Limited reported revenue of ₹8.47 Cr (up 27% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · ConsolidatedRevenue
₹8.47 Cr
+27.0% YoY
EBITDA
₹0.04 Cr
-94.8% YoY
Profit After Tax
−₹0.73 Cr
-343.3% YoY
Net Worth
₹8.10 Cr
-8.0% YoY
Total Assets
₹15.09 Cr
+27.2% YoY
Total Debt
₹6.89 Cr
+132.0% YoY
Revenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 |
|---|---|---|
| Income statement | ||
| Revenue | 8.47 | 6.67 |
| Revenue growth | +27.0% | - |
| EBITDA | 0.04 | 0.77 |
| EBITDA margin | +0.5% | +11.5% |
| Profit before tax | (0.70) | 0.40 |
| Net profit | (0.73) | 0.30 |
| Net profit margin | -8.6% | +4.5% |
| EPS (₹) | (0.85) | 0.68 |
| Balance sheet | ||
| Total assets | 15.09 | 11.86 |
| Net worth | 8.10 | 8.80 |
| Total debt | 6.89 | 2.97 |
| Cash & bank | 0.17 | 0.10 |
| Net working capital | 4.47 | 3.38 |
| Cash flow | ||
| Cash from operations | (0.71) | (1.76) |
| Cash from investing | (2.93) | (6.21) |
| Cash from financing | 3.72 | 8.00 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | 8.52 | 6.67 | 6.48 | 5.58 | 5.34 |
| Revenue growth | +27.7% | +2.9% | +16.1% | +4.5% | - |
| EBITDA | 0.12 | 0.76 | 1.19 | 0.86 | 0.61 |
| EBITDA margin | +1.4% | +11.4% | +18.4% | +15.4% | +11.4% |
| Profit before tax | (0.61) | 0.39 | 0.67 | 0.35 | 0.09 |
| Net profit | (0.65) | 0.29 | 0.52 | 0.35 | 0.11 |
| Net profit margin | -7.6% | +4.4% | +8.0% | +6.3% | +2.1% |
| EPS (₹) | (0.75) | 0.68 | 2.55 | 2.39 | 0.81 |
| Balance sheet | |||||
| Total assets | 14.69 | 11.86 | 4.46 | 3.15 | 3.10 |
| Net worth | 8.18 | 8.80 | 3.34 | 1.36 | 1.01 |
| Total debt | 6.40 | 2.97 | 1.05 | 1.74 | 2.04 |
| Cash & bank | 0.03 | 0.10 | 0.06 | 0.05 | 0.05 |
| Net working capital | 4.09 | 3.38 | 1.78 | 0.42 | 0.79 |
| Cash flow | |||||
| Cash from operations | (0.37) | (1.76) | (0.29) | 1.23 | 0.33 |
| Cash from investing | (2.93) | (6.21) | (0.37) | (0.75) | 0.51 |
| Cash from financing | 3.23 | 8.00 | 0.67 | (0.48) | (0.94) |
Financial Statements
Figures in ₹ Cr; negatives in brackets. Updated 29 Oct 2026
| Particulars | FY 2025-26 | FY 2024-25 |
|---|---|---|
| Revenue | 8.47 | 6.67 |
| Revenue growth | +27.0% | - |
| Other income | 0.33 | 0.15 |
| Total expenses | 8.43 | 5.90 |
| Employee cost | 2.45 | 1.81 |
| EBITDA | 0.04 | 0.77 |
| EBITDA margin | +0.5% | +11.5% |
| Depreciation | 0.82 | 0.38 |
| Interest | 0.25 | 0.14 |
| Profit before tax | (0.70) | 0.40 |
| Tax | 0.03 | 0.10 |
| Net profit | (0.73) | 0.30 |
| Net profit margin | -8.6% | +4.5% |
| EPS (₹) | (0.85) | 0.68 |
| Particulars | FY 2025-26 | FY 2024-25 |
|---|---|---|
| Equity & liabilities | ||
| Share capital | 8.71 | 4.36 |
| Reserves & surplus | (0.61) | 4.44 |
| Shareholders' funds (net worth) | 8.10 | 8.80 |
| Minority interest | 0.00 | 0.00 |
| Secured loans | 2.97 | 2.55 |
| Unsecured loans | 3.92 | 0.42 |
| Total debt | 6.89 | 2.97 |
| Total liabilities | 15.09 | 11.86 |
| Assets | ||
| Gross block | 13.81 | 7.18 |
| Net block | 9.10 | 2.49 |
| Capital work in progress | 1.08 | 3.38 |
| Investments | 0.07 | 0.00 |
| Inventories | 2.58 | 2.38 |
| Sundry debtors | 1.59 | 1.19 |
| Cash & bank balances | 0.17 | 0.10 |
| Loans & advances | 0.96 | 0.64 |
| Total current assets | 5.30 | 4.31 |
| Total current liabilities | 0.83 | 0.93 |
| Net working capital | 4.47 | 3.38 |
| Total assets | 15.09 | 11.86 |
| Particulars | FY 2025-26 | FY 2024-25 |
|---|---|---|
| Opening cash | 0.10 | 0.06 |
| Net cash from operating activities | (0.71) | (1.76) |
| Net cash from investing activities | (2.93) | (6.21) |
| Net cash from financing activities | 3.72 | 8.00 |
| Net change in cash | 0.07 | 0.04 |
| Closing cash | 0.17 | 0.10 |
| Particulars | FY 2025-26 | FY 2024-25 |
|---|---|---|
| Growth | ||
| Sales growth | +27.0% | - |
| EBITDA growth | -94.8% | - |
| PBT growth | - | +9997.0% |
| Net income growth | -343.3% | - |
| Profitability & leverage | ||
| Net income margin | -8.6% | +4.5% |
| Return on capital employed | 0.0% | +4.6% |
| Return on net worth | 0.0% | +3.4% |
| Debt / equity | 0.58 | 0.34 |
| Long-term debt / equity | 0.36 | 0.23 |
| Interest cover | -32.05 | 35.90 |
| Efficiency & per share | ||
| Fixed asset turnover | 0.81 | 0.93 |
| Inventory turnover | 3.42 | 2.80 |
| Debtors turnover | 6.09 | 5.61 |
| EPS (₹) | (0.85) | 0.68 |
| Dividend per share (₹) | 0.00 | 0.00 |
| Book value per share (₹) | 9.30 | 20.20 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|---|---|
| Revenue | 8.52 | 6.67 | 6.48 | 5.58 | 5.34 |
| Revenue growth | +27.7% | +2.9% | +16.1% | +4.5% | - |
| Other income | 0.33 | 0.15 | 0.03 | 0.01 | 0.00 |
| Total expenses | 8.40 | 5.91 | 5.29 | 4.72 | 4.73 |
| Employee cost | 2.14 | 1.81 | 1.64 | 1.79 | 1.69 |
| EBITDA | 0.12 | 0.76 | 1.19 | 0.86 | 0.61 |
| EBITDA margin | +1.4% | +11.4% | +18.4% | +15.4% | +11.4% |
| Depreciation | 0.81 | 0.38 | 0.40 | 0.34 | 0.33 |
| Interest | 0.25 | 0.14 | 0.15 | 0.18 | 0.19 |
| Profit before tax | (0.61) | 0.39 | 0.67 | 0.35 | 0.09 |
| Tax | 0.04 | 0.10 | 0.15 | 0.00 | (0.02) |
| Net profit | (0.65) | 0.29 | 0.52 | 0.35 | 0.11 |
| Net profit margin | -7.6% | +4.4% | +8.0% | +6.3% | +2.1% |
| EPS (₹) | (0.75) | 0.68 | 2.55 | 2.39 | 0.81 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|---|---|
| Equity & liabilities | |||||
| Share capital | 8.71 | 4.36 | 1.96 | 1.50 | 1.50 |
| Reserves & surplus | (0.53) | 4.44 | 1.38 | (0.14) | (0.49) |
| Shareholders' funds (net worth) | 8.18 | 8.80 | 3.34 | 1.36 | 1.01 |
| Secured loans | 2.75 | 2.55 | 0.89 | 1.30 | 1.65 |
| Unsecured loans | 3.65 | 0.42 | 0.16 | 0.44 | 0.39 |
| Total debt | 6.40 | 2.97 | 1.05 | 1.74 | 2.04 |
| Total liabilities | 14.69 | 11.86 | 4.46 | 3.15 | 3.10 |
| Assets | |||||
| Gross block | 10.57 | 5.05 | 4.71 | 4.35 | 3.72 |
| Net block | 7.19 | 2.48 | 2.53 | 2.60 | 2.16 |
| Capital work in progress | 1.08 | 3.38 | 0.00 | 0.00 | 0.00 |
| Investments | 2.04 | 0.00 | 0.00 | 0.00 | 0.04 |
| Inventories | 2.44 | 2.38 | 1.23 | 0.37 | 0.57 |
| Sundry debtors | 1.21 | 1.19 | 0.99 | 0.76 | 0.69 |
| Cash & bank balances | 0.03 | 0.10 | 0.06 | 0.05 | 0.05 |
| Loans & advances | 0.94 | 0.64 | 0.16 | 0.05 | 0.03 |
| Total current assets | 4.62 | 4.31 | 2.44 | 1.23 | 1.34 |
| Total current liabilities | 0.53 | 0.93 | 0.66 | 0.81 | 0.55 |
| Net working capital | 4.09 | 3.38 | 1.78 | 0.42 | 0.79 |
| Total assets | 14.69 | 11.86 | 4.46 | 3.15 | 3.10 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|---|---|
| Opening cash | 0.10 | 0.06 | 0.05 | 0.05 | 0.15 |
| Net cash from operating activities | (0.37) | (1.76) | (0.29) | 1.23 | 0.33 |
| Net cash from investing activities | (2.93) | (6.21) | (0.37) | (0.75) | 0.51 |
| Net cash from financing activities | 3.23 | 8.00 | 0.67 | (0.48) | (0.94) |
| Net change in cash | (0.06) | 0.04 | 0.01 | 0.00 | (0.10) |
| Closing cash | 0.03 | 0.10 | 0.06 | 0.05 | 0.05 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|---|---|
| Growth | |||||
| Sales growth | +27.7% | +2.9% | +16.1% | +4.5% | - |
| EBITDA growth | -84.2% | -36.1% | +38.4% | +41.0% | - |
| PBT growth | - | -41.8% | +91.4% | +288.9% | +9997.0% |
| Net income growth | -324.1% | -44.2% | +48.6% | +218.2% | - |
| Revenue CAGR (3Y) | +15.2% | +7.7% | - | - | - |
| EBITDA CAGR (3Y) | -48.1% | +7.6% | - | - | - |
| Profitability & leverage | |||||
| Net income margin | -7.6% | +4.4% | +8.0% | +6.3% | +2.1% |
| Return on capital employed | 0.0% | +6.7% | +20.7% | +15.7% | +8.1% |
| Return on net worth | 0.0% | +4.9% | +20.7% | +24.0% | +8.0% |
| Debt / equity | 0.55 | 0.33 | 0.59 | 1.59 | 2.02 |
| Long-term debt / equity | 0.34 | 0.19 | 0.16 | 0.53 | 0.78 |
| Interest cover | -36.23 | 36.84 | 18.99 | 34.62 | 67.86 |
| Efficiency & per share | |||||
| Fixed asset turnover | 1.09 | 1.37 | 1.43 | 1.38 | 1.44 |
| Inventory turnover | 3.54 | 3.70 | 8.10 | 11.87 | 9.37 |
| Debtors turnover | 7.10 | 6.12 | 7.41 | 7.70 | 7.74 |
| EPS (₹) | (0.75) | 0.68 | 2.55 | 2.39 | 0.81 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 9.39 | 20.20 | 17.06 | 9.09 | 6.70 |
To see the full year-wise statements and ratios of Hamps Bio Limited, buy the company report.
Board of directors of Hamps Bio Limited
Hamps Bio has 5 current directors and 5 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Shrenikkumar Mountkumar Shah Also directs: V4u Healthcare Private Limited | Whole-Time Director | 02 Jan 2007 | 19 Years 9 Months | Current |
| Herrik Mountbaton Shah Also directs: V4u Healthcare Private Limited, HSDL Innovative Private Limited | Managing Director | 02 Jan 2007 | 19 Years 9 Months | Current |
| Shivali Rajpurohit | Director | 25 Aug 2025 | 1 Years 2 Months | Current |
| Pallavi Herrik Shah | Director | 15 Jun 2024 | 2 Years 4 Months | Current |
| Jinay Dipakkumar Palrecha | Director | 04 Nov 2023 | 2 Years 11 Months | Current |
Peer comparison
Hamps Bio Limited is compared with the 6 companies closest to it by revenue in the Food and Beverages industry (Instant Foods, Pharma Retail and Distribution), with the same principal business activity (wholesale trading), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Hamps Bio Limitedthis company | ₹8.47 Cr (FY 2026) | -₹73 Lakh | -8.6% | 27.0% | Ankleshwar, Gujarat, India | |
| Aktis Pharma India Private Limited | ₹6.85 Cr (FY 2025) | 12.0% | Hyderabad, Telangana, India | |||
| Bhairav Health and Wellness Private Limited | ₹6.83 Cr (FY 2020) | 13.0% | Panvel, Maharashtra, India | |||
| Clivia Pharma Private Limited | ₹6.83 Cr (FY 2025) | 50.0% | Palarivattom, Kerala, India | |||
| Nirkm Healthcare Private Limited | ₹6.83 Cr (FY 2025) | 0.0% | Ernakulam, Kerala, India | |||
| Riden Healthcare Private Limited | ₹6.82 Cr (FY 2025) | 13.0% | South Extension, Delhi, India | |||
| Chandravim Exim Private Limited | ₹6.81 Cr (FY 2025) | -38.0% | Mumbai, Maharashtra, India |
To see the full peer comparison of Hamps Bio Limited, buy the company report.
Charges & borrowings
Open charges
₹4.83 Cr
Satisfied charges
None
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 10 Aug 2017 | 100125029 | Others | ₹4.83 Cr | Open |
To see the full charge records of Hamps Bio Limited, buy the company report.
Total charge records: 1 View all charges
Deals & funding
Hamps Bio Limited has 11 deals on record (10 market trades, 1 ipo); the latest was in July 2025.
Total deals
11
Market trades
10
IPO
1
Deals on record (5 of 11)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Jul 2025 | Market trade | ₹25.8 Lakh | Buyer: Multiplier Share and Stock Advisors Private Limited Seller: Multiplier Share and Stock Advisors Private Limited |
| Jan 2025 | Market trade | ₹14.1 Lakh | Seller: Mansi Share and Stock Broking Private Limited |
| Jan 2025 | Market trade | ₹24.3 Lakh | Seller: Mansi Share and Stock Broking Private Limited |
| Jan 2025 | Market trade | ₹58.9 Lakh | Seller: Mansi Share and Stock Broking Private Limited |
| Jan 2025 | Market trade | ₹95.2 Lakh | Buyer: Mansi Share and Stock Broking Private Limited Seller: Multiplier Share and Stock Advisors Private Limited , Ishaan Tradefin LLP |
To see the full deal history of Hamps Bio Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
No court or tribunal cases involving Hamps Bio Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Hamps Bio Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
Hamps Bio has 1 GST registration: 1 active.
Total GSTINs
1
Active
1
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 24AABCH8058B1ZW | Gujarat | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Hamps Bio Limited, buy the company report.
Recent activity
Hamps Bio Limited has 10 board changes on record since 2007: 5 appointments and 5 cessations. The latest: Shivali Rajpurohit ceased to be Additional Director on 23 Nov 2025.
Charges
A charge with Others of Rs. 4.83 Cr registered on 10 Aug 2017 with Charge ID 100125029 was modified on 21 Jul 2026.
Filing
Hamps Bio Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Ahmedabad.
Ceased
Shivali Rajpurohit ceased to be Additional Director.
AGM
Hamps Bio Limited last Annual general meeting of members was held on 30 Aug 2025 as per latest MCA records.
Appointed
Shivali Rajpurohit was appointed as Director.
Appointed
Pallavi Herrik Shah was appointed as Director.
Ceased
Shrenikkumar Mountkumar Shah ceased to be Director.
Ceased
Jinay Dipakkumar Palrecha ceased to be Additional Director.
Ceased
Radhika Arun Kanodiya ceased to be Additional Director.
Appointed
Jinay Dipakkumar Palrecha was appointed as Director.
Ceased
Herrik Mountbaton Shah ceased to be Director.
Charges
A charge with Others amounted to Rs. 4.83 Cr with Charge ID 100125029 was registered on 10 Aug 2017.
3 earlier events are in the company report.
Frequently asked questions
Hamps Bio is an active public limited company based in Ankleshwar, Gujarat, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 02 January 2007 (19+ years old) and is registered under CIN L24233GJ2007PLC049692. Listed on BSE: 544312.
Hamps Bio reported revenue of ₹8.47 Cr for FY 2025-26 (up 27% YoY) based on consolidated financials.
Hamps Bio has 5 current directors:
- Herrik Mountbaton Shah - Managing Director
- Shrenikkumar Mountkumar Shah - Whole-Time Director
- Shivali Rajpurohit - Director
- Pallavi Herrik Shah - Director
- Jinay Dipakkumar Palrecha - Director
The latest financial statements of Hamps Bio on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 30 August 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Hamps Bio is 24AABCH8058B1ZW, registered in Gujarat.
The CIN (Corporate Identification Number) of Hamps Bio is L24233GJ2007PLC049692. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Hamps Bio is a listed company as per MCA records. Its shares are listed on BSE (code: 544312).
Hamps Bio was incorporated on 02 January 2007, making it 19+ years old. It is registered with the Registrar of Companies, Ahmedabad.
Hamps Bio has 11 deals on record (10 market trades, 1 ipo); the latest was in July 2025.
The peers of Hamps Bio by revenue are Aktis Pharma India Private Limited, Bhairav Health and Wellness Private Limited, Clivia Pharma Private Limited, Nirkm Healthcare Private Limited, Riden Healthcare Private Limited and 1 more, all in the Food and Beverages industry (Instant Foods, Pharma Retail and Distribution), with the same principal business activity (wholesale trading).
Shivali Rajpurohit ceased to be Additional Director on 23 Nov 2025. Shivali Rajpurohit was appointed as Director on 25 Aug 2025. Pallavi Herrik Shah was appointed as Director on 15 Jun 2024. Hamps Bio has 10 board changes on record in total.